The Biomarker: Melanoma

Sanjiv S. Agarwala, MD
Video Categories: The Biomarker

PMO is pleased to offer the department “The Biomarker” to discuss the identification of biomarkers in patients with cancer and the prognostic/predictive impact and clinical decision-making implications of that marker. This month, we focus on KIT mutations in melanoma patients. Dr Sanjiv Agarwala provides his insights on this provocative topic.

March 31, 2015

Reality of the ASPIRE Study

Ajai Chari, MD, at the Mount Sinai School of Medicine in New York, deliberates on the results of the ASPIRE study as the most important thing to come out of ASH for the myeloma community. He mentions that although the study has very positive indications, the therapy isn’t really appropriate [ Read More ]

October 7, 2016

Common Issues in Treating Patients with HR+/ HER2-Negative Metastatic Breast Cancer

Dr Hope Rugo discusses some of the choices and challenges she’s faced with in treating patients with HR+/ HER2-negative metastatic breast cancer with the goal of helping patients live as long as possible and with the best quality of life.